6IGF

Crystal structure of Human Papillomavirus type 52 pentamer

Summary for 6IGF

• Entry DOI: 10.2210/pdb6igf/pdb
• Descriptor: Major capsid protein L1 (1 entity in total)
• Functional Keywords: human papillomavirus type 52 capsid protein, structural protein
• Biological source: Human papillomavirus type 52
• Total number of polymer chains: 10
• Total formula weight: 595336.76

Authors

Li, Z.H.,Song, S.,He, M.Z.,Gu, Y.,Li, S.W. (deposition date: 2018-09-25, release date: 2018-11-28, Last modification date: 2023-11-22)

Primary citation

Li, Z.,Song, S.,He, M.,Wang, D.,Shi, J.,Liu, X.,Li, Y.,Chi, X.,Wei, S.,Yang, Y.,Wang, Z.,Li, J.,Qian, H.,Yu, H.,Zheng, Q.,Yan, X.,Zhao, Q.,Zhang, J.,Gu, Y.,Li, S.,Xia, N.
Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
Nat Commun, 9:5360-5360, 2018

PubMed Abstract: Sequence variability in surface-antigenic sites of pathogenic proteins is an important obstacle in vaccine development. Over 200 distinct genomic sequences have been identified for human papillomavirus (HPV), of which more than 18 are associated with cervical cancer. Here, based on the high structural similarity of L1 surface loops within a group of phylogenetically close HPV types, we design a triple-type chimera of HPV33/58/52 using loop swapping. The chimeric VLPs elicit neutralization titers comparable with a mix of the three wild-type VLPs both in mice and non-human primates. This engineered region of the chimeric protein recapitulates the conformational contours of the antigenic surfaces of the parental-type proteins, offering a basis for this high immunity. Our stratagem is equally successful in developing other triplet-type chimeras (HPV16/35/31, HPV56/66/53, HPV39/68/70, HPV18/45/59), paving the way for the development of an improved HPV prophylactic vaccine against all carcinogenic HPV strains. This technique may also be extrapolated to other microbes.

PubMed: 30560935
DOI: 10.1038/s41467-018-07199-6

Experimental method

X-RAY DIFFRACTION (2.751 Å)